Latest William K. Oh Stories
AFFINITY Trial to Continue as Planned Following Completion of Interim Futility Analysis BOTHELL, Wash. and VANCOUVER, British Columbia, Jan.
Key evaluation to inform the US Food and Drug Administration regulatory submission SYDNEY, Sept.
A genetic discovery out of the University of Pittsburgh School of Medicine is leading to a highly accurate test for aggressive prostate cancer and identifies new avenues for treatment.
LONDON, June 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Phase III Trial Now Recruiting Patients SANTA ROSA, Calif., April 15, 2014 /PRNewswire/ -- A phase III clinical trial conducted at the Meir Medical Center in Kfar-Saba, Israel is now
ResearchMoz.us include new market research report "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" to its huge
-- Peak US urology organisation CUSP Group, LLC to evaluate MiStat(TM) technology SYDNEY, April 8, 2014 /PRNewswire/ -- Private Australian biotechnology company Minomic International
BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc.
Multiple Studies of Decipher Prostate Cancer Classifier Presented at 2014 ASCO Genitourinary Symposium SAN DIEGO, Jan.